Predictors of treatment failure and clinical stability in patients with community acquired pneumonia

Annals of Translational Medicine

Volumn 5, Issue 22, 2017, Pages

  Morley, Deirdre ^a   Torres, Antoni ^b,c   Cillóniz, Catia ^b,c   Martin Loeches, Ignacio ^a,d  

^a ST JAMES S HOSPITAL   (Ireland)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Biomarkers; Community acquired pneumonia (CAP); Pneumonia; Procalcitonin (PCT); Sepsis; Treatment failure (TF)

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; PROCALCITONIN;

CLINICAL ASSESSMENT; COMMUNITY ACQUIRED PNEUMONIA; DISEASE COURSE; DISEASE SEVERITY; HOSPITAL ADMISSION; HUMAN; MORTALITY; PATIENT CARE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SIGNAL TRANSDUCTION; TREATMENT FAILURE; UPREGULATION;

EID: 85035792434     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2017.06.54     Document Type: Review

References (102)

1. Wunderink RG, Waterer GW. Community-acquired pneumonia. N Engl J Med 2014;370:1863
2. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41
3. Rello J, Rodriguez R, Jubert P, et al. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis 1996;23:723-8
4. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72
5. Roson B, Carratala J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001;33:158-65
6. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013;309:355-63
7. Takada K, Matsumoto S, Kojima E, et al. Predictors and impact of time to clinical stability in community-acquired pneumococcal pneumonia. Respir Med 2014;108:806-12
8. Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59:960-5
9. Menendez R, Torres A. Treatment failure in community-acquired pneumonia. Chest 2007;132:1348-55
10. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015;313:677-86
11. Menendez R, Torres A, Rodriguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004;39:1783-90
12. Genne D, Kaiser L, Kinge TN, et al. Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. Clin Microbiol Infect 2003;9:949-54
13. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;279:1452-7
14. Aliberti S, Zanaboni AM, Wiemken T, et al. Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. Eur Respir J 2013;42:742-9
15. Hougham GW, Ham SA, Ruhnke GW, et al. Sequence patterns in the resolution of clinical instabilities in community-acquired pneumonia and association with outcomes. J Gen Intern Med 2014;29:563-71
16. Finch S, Chalmers JD. Brief Clinical Review: Non Responding Pneumonia. EMJ Respir 2014;2:104-11
17. Garcia-Vidal C, Carratala J. Early and late treatment failure in community-acquired pneumonia. Semin Respir Crit Care Med 2009;30:154-60
18. Kolditz M, Ewig S, Hoffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 2013;41:974-84
19. Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care 2012;16:R141
20. Aujesky D, Fine MJ. The pneumonia severity index: a decade after the initial derivation and validation. Clin Infect Dis 2008;47 Suppl 3:S133-9
21. Schuetz P, Koller M, Christ-Crain M, et al. Predicting mortality with pneumonia severity scores: importance of model recalibration to local settings. Epidemiol Infect 2008;136:1628-37
22. Kolditz M, Ewig S, Klapdor B, et al. Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax 2015;70:551-8
23. Guo Q, Li HY, Zhou YP, et al. CURB-65 score predicted mortality in community-acquired pneumonia better than IDSA/ATS minor criteria in a low-mortality-rate setting. Eur J Clin Microbiol Infect Dis 2012;31:3281-6
24. Akram AR, Chalmers JD, Taylor JK, et al. An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia. Clin Microbiol Infect 2013;19:1174-80
25. Menendez R, Martinez R, Reyes S, et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009;64:987-92
26. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801-10
27. Povoa P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med 2002;28:235-43
28. Povoa P, Teixeira-Pinto AM, Carneiro AH. C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study. Crit Care 2011;15:R169
29. Zobel K, Martus P, Pletz MW, et al. Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ. BMC Pulm Med 2012;12:6
30. Andrijevic I, Matijasevic J, Andrijevic L, et al. Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia. Ann Thorac Med 2014;9:162-7
31. Prucha M, Bellingan G, Zazula R. Sepsis biomarkers. Clin Chim Acta 2015;440:97-103
32. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54
33. Moya F, Nieto AJLRC. Calcitonin biosynthesis: evidence for a precursor. Eur J Biochem 1975;55:407-13
34. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-17
35. Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007;7:10
36. McLean AS, Tang B, Huang SJ. Investigating sepsis with biomarkers. BMJ 2015;350:h254
37. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-36
38. Meisner M. Update on procalcitonin measurements. Ann Lab Med 2014;34:263-73
39. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008;121:219-25
40. Almirall J, Bolibar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004;125:1335-42
41. Sankar V, Webster NR. Clinical application of sepsis biomarkers. J Anesth 2013;27:269-83
42. Kruger S, Ewig S, Kunde J, et al. Assessment of inflammatory markers in patients with community-acquired pneumonia-influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. Clin Chim Acta 2010;411:1929-34
43. Guervilly C, Coisel Y, Botelho-Nevers E, et al. Significance of high levels of procalcitonin in patients with influenza A (H1N1) pneumonia. J Infect 2010;61:355-8
44. Corsonello A, Luciani F, Incalzi RA. Biomarkers in community-acquired pneumonia: does chronic kidney disease matter? Am J Respir Crit Care Med 2011;183:1734; author response-5
45. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264-74
46. Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011;52 Suppl 4:S346-50
47. Rodriguez AH, Aviles-Jurado FX, Diaz E, et al. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis. J Infect 2016;72:143-51
48. Sankar V, Webster NR. Clinical application of sepsis biomarkers. J Anesth 2013;27:269-83
49. Silvestre JP, Coelho LM, Povoa PM. Impact of fulminant hepatic failure in C-reactive protein? J Crit Care 2010;25:657.e7-12
50. El-Solh AA, Vora H, Knight PR 3rd, et al. Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes. Crit Care Med 2011;39:1251-6
51. Christ-Crain M, Muller B. Procalcitonin in bacterial infections-hype, hope, more or less? Swiss Med Wkly 2005;135:451-60
52. Tang BM, Eslick GD, Craig JC, et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-7
53. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008;52:48-58.e2
54. Simpson RJ, Hammacher A, Smith DK, et al. Interleukin-6: structure-function relationships. Protein Sci 1997;6:929-55
55. Hack CE, De Groot ER, Felt-Bersma RJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989;74:1704-10
56. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64
57. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010;22:347-52
58. Menendez R, Martinez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009;64:587-91
59. Menendez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008;63:447-52
60. Suresh MV, Singh SK, Ferguson DA, Jr., et al. Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. J Immunol 2007;178:1158-63
61. Que YA, Virgini V, Lozeron ED, et al. Low C-reactive protein values at admission predict mortality in patients with severe community-acquired pneumonia caused by Streptococcus pneumoniae that require intensive care management. Infection 2015;43:193-9
62. Bruns AH, Oosterheert JJ, Hak E, et al. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008;32:726-32
63. Coelho LM, Salluh JI, Soares M, et al. Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care 2012;16:R53
64. Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006;32:469-72
65. Charles PE, Tinel C, Barbar S, et al. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 2009;13:R38
66. Martin-Loeches I, Valles X, Menendez R, et al. Predicting treatment failure in patients with community acquired pneumonia: a case-control study. Respir Res 2014;15:75
67. Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006;34:2596-602
68. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131:9-19
69. Tang J, Long W, Yan L, et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infect Dis 2013;13:596
70. Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012;172:715-22
71. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93
72. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302:1059-66
73. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-7
74. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016;16:819-27
75. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463-74
76. Schuetz P, Chiappa V, Briel M, et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011;171:1322-31
77. Ramirez P, Ferrer M, Marti V, et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011;39:2211-7
78. Walley KR. Biomarkers in sepsis. Curr Infect Dis Rep 2013;15:413-20
79. Povoa P, Salluh JI. Use of biomarkers in sepsis: many questions, few answers. Rev Bras Ter Intensiva 2013;25:1-2
80. Seligman R, Papassotiriou J, Morgenthaler NG, et al. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 2008;12:R11
81. Schluter B, Raufhake C, Erren M, et al. Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002;30:32-7
82. Gallagher PM, Lowe G, Fitzgerald T, et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003;58:154-6
83. Martin-Loeches I, Sole-Violan J, Rodriguez de Castro F, et al. Variants at the promoter of the interleukin-6 gene are associated with severity and outcome of pneumococcal community-acquired pneumonia. Intensive Care Med 2012;38:256-62
84. Struck J, Tao C, Morgenthaler NG, et al. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004;25:1369-72
85. Wang P. Adrenomedullin in sepsis and septic shock. Shock 1998;10:383-4
86. Martinez A, Pio R, Zipfel PF, et al. Mapping of the adrenomedullin-binding domains in human complement factor H. Hypertens Res 2003;26 Suppl:S55-9
87. Morgenthaler NG, Muller B, Struck J, et al. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219-26
88. Katan M, Muller B, Christ-Crain M. Copeptin: a new and promising diagnostic and prognostic marker. Crit Care 2008;12:117
89. Muller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007;37:145-52
90. Cavallazzi R, El-Kersh K, Abu-Atherah E, et al. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review. Respir Med 2014;108:1569-80
91. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006;10:R96
92. Gordo-Remartinez S, Calderon-Moreno M, Fernandez-Herranz J, et al. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia. PLoS One 2015;10:e0125212
93. Claessens YE, Mathevon T, Kierzek G, et al. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia. Intensive Care Med 2010;36:799-809
94. Kolditz M, Halank M, Schulte-Hubbert B, et al. Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumonia. Respir Med 2012;106:1320-8
95. Kruger S, Ewig S, Kunde J, et al. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax 2010;65:208-14
96. Kabrhel C, Mark Courtney D, Camargo CA Jr, et al. Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med 2010;17:589-97
97. Querol-Ribelles JM, Tenias JM, Grau E, et al. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest 2004;126:1087-92
98. Snijders D, Schoorl M, Schoorl M, et al. D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial. Eur J Intern Med 2012;23:436-41
99. Yang Y, Xie J, Guo F, et al. Combination of C-reactive protein, procalcitonin and sepsis-related organ failure score for the diagnosis of sepsis in critical patients. Ann Intensive Care 2016;6:51
100. Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008;31:349-55
101. Antunes G, Evans SA, Lordan JL, et al. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002;20:990-5
102. Kox WJ, Volk T, Kox SN, et al. Immunomodulatory therapies in sepsis. Intensive Care Med 2000;26 Suppl 1:S124-8